&nbsp;

Jul 2025

Drug

atezolizumab (subcut)

Other Name(s): Tecentriq® SC

Quick Link(s):

Jul 2025

Drug

atezolizumab

Other Name(s): Tecentriq™

Quick Link(s):

Jul 2025

Drug

niLOtinib

Other Name(s): Tasigna®

Quick Link(s):

Jul 2025

Regimen

NILO

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

niLOtinib - Chronic phase Ph+ CML, with specific criteria

Exceptional Access Program

niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria

Drugs Used:

niLOtinib

Quick Link(s):

Regimen Monograph

Jul 2025

Regimen

NIVL+IPIL

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Drugs Used:

nivolumab (Unfunded),

ipilimumab (Unfunded)

Quick Link(s):

Jul 2025

Regimen

NIVL+IPIL

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma

New Drug Funding Program

Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Jul 2025

Regimen

NIVL+IPIL

Cancer Type:

Skin,

Melanoma

Intent: Adjuvant

Drugs Used:

nivolumab (Unfunded),

ipilimumab (Unfunded)

Quick Link(s):

Jul 2025

Regimen

NIVL+IPIL

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)

New Drug Funding Program

Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Jul 2025

Regimen

NIVL+IPIL

Cancer Type:

Lung,

Mesothelioma (Pleural)

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - Advanced Malignant Pleural Mesothelioma

New Drug Funding Program

Nivolumab plus Ipilimumab - Advanced Malignant Pleural Mesothelioma

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Jul 2025

Regimen

ABIRPRED

Cancer Type:

Genitourinary,

Prostate

Intent: Adjuvant, Curative

Funding:

ODB - General Benefit

abiraterone

ODB - General Benefit

prednisone

Drugs Used:

abiraterone,

prednisone

Quick Link(s):

Regimen Monograph

Jul 2025

Regimen

ASCI

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

asciminib - For the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, based on criteria

Drugs Used:

asciminib